Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia
Natalia L. Komarova, Allen A. Katouli, Dominik Wodarz · 2009
Read Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia by Natalia L. Komarova, Allen A. Katouli, Dominik Wodarz (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004423.txt.
Description
Three targeted drugs, taken in pairs or all at once, are weighed in a 2009 PLOS ONE study of chronic myeloid leukemia by Natalia Komarova, Allen Katouli, and Dominik Wodarz. This blood cancer is treated fairly well by the drug imatinib. Trouble comes when the cancer mutates and stops responding to the drug.
Two more targeted drugs were ready to add, so the key question was how to combine them. Using math models of how resistance grows, the authors compared pairs against the triple mix. Their answer, given in the title, is that two drugs together can improve therapy, but three cannot. That kind of result helps doctors plan drug use and slow the rise of resistant cancer.
Catalog record
| CREATOR | Natalia L. Komarova, Allen A. Katouli, Dominik Wodarz |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004423